Skip to main content

Table 2 Utility values of the health states [53, 54]

From: Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections

Health state Utility Source & calculation
PP1M
Stable: Adherent 0.865 Layperson sample
Stable: Non-adherent 0.865 Assumed equal to Stable: Adherent
Relapse: Hospitalization 0.479 Layperson sample
Relapse: Ambulatory care 0.479 Layperson sample
Death 0.000 Assumed 0.000
PP3M
Stable: Adherent 0.916 Layperson sample and added benefit for time between injections
Stable: Non-adherent 0.865 Assumed equal to Stable: Adherent
Relapse: Hospitalization 0.479 Layperson sample
Relapse: Ambulatory care 0.479 Layperson sample
Death 0.000 Assumed 0.000
Treatment Interruption
Stable: Adherent 0.865 Layperson sample
Stable: Non-adherent 0.865 Assumed equal to Stable: Adherent
Relapse: Hospitalization 0.479 Layperson sample
Relapse: Ambulatory care 0.479 Layperson sample
Death 0.000 Assumed 0.000
Utility decrements for adverse events
Acute EPS 0.291 Layperson sample (0.865–0.574)
Weight gain 0.086 Layperson sample (0.865–0.779)
Diabetes 0.153 Layperson sample (0.865–0.712)
  1. Abbreviations: PP1M, paliperidone palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; EPS, Extrapyramidal Symptoms